New hope for mesothelioma patients: targeted drug aims to shrink tumors
NCT ID NCT07602946
First seen May 22, 2026 · Last updated May 22, 2026
Summary
This study tests a drug called BMS-986504 in people with a type of mesothelioma that has returned after initial treatment. It is for patients whose tumors have a specific genetic change (MTAP deficiency). The goal is to see if the drug can shrink tumors or stop them from growing. About 30 adults will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MESOTHELIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Leicester Royal Infirmary
Leicester, , LE1 5WW, United Kingdom
Conditions
Explore the condition pages connected to this study.